Androgen Receptor Antagonist
Showing 1 - 25 of >10,000
Prostate Cancer, Prostate Adenocarcinoma Trial (drug, other, procedure)
Not yet recruiting
- Prostate Cancer
- Prostate Adenocarcinoma
- Relacorilant
- +4 more
- (no location specified)
Feb 2, 2023
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate Trial in United States (TRC253)
Completed
- Metastatic Castrate-resistant Prostate Cancer
- Adenocarcinoma, Prostate
-
Birmingham, Alabama
- +4 more
Mar 29, 2021
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 4, 2023
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma Trial in United States (GnRH
Recruiting
- Castration-Resistant Prostatic Cancer
- +4 more
- GnRH agonist/antagonist
- +3 more
-
Los Angeles, California
- +3 more
Apr 30, 2021
Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)
Not yet recruiting
- Urothelial Carcinoma Bladder
- Androgen Receptor Positive
- Degarelix
- Gemcitabine/Cisplatin
-
Providence, Rhode IslandLifespan Cancer Institute
May 1, 2023
Breast Cancer With or Without BRCA Mutation
Recruiting
- Breast Cancer
- Androgen receptor status and BRCA mutation
-
Varanasi, UP, IndiaBanaras Hindu University
Jun 2, 2022
Pancreatic Cancer Trial in Tampa (Enzalutamide, Gemcitabine, Nab-paclitaxel)
Completed
- Pancreatic Cancer
- Enzalutamide
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Aug 16, 2021
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston
Recruiting
- Advanced Breast Carcinoma
- +17 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
LARS - Low Anterior Resection Syndrome Trial in Seoul (Ramosetron)
Not yet recruiting
- LARS - Low Anterior Resection Syndrome
-
Seoul, Jongro-gu, Korea, Republic ofSeoul National University Hospital
Dec 13, 2022
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of
Not yet recruiting
- Triple Negative Breast Cancer
- +2 more
- Everolimus
- Investigator's Choice of Chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 25, 2023
Physical Function During ARSI Treatment
Recruiting
- Advanced Prostate Carcinoma
- androgen receptor signaling inhibitors
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Nov 8, 2022
Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)
Recruiting
- Salivary Gland Carcinoma
- Goserelin Acetate
- Pembrolizumab
-
Chicago, Illinois
- +6 more
Sep 22, 2022
Androgen Deprivation Therapy, Prostate Cancer, Hypertension Trial (Gonadotropin-Releasing Hormone Agonist, Androgen receptor
Not yet recruiting
- Androgen Deprivation Therapy
- +4 more
- Gonadotropin-Releasing Hormone Agonist
- +2 more
- (no location specified)
Jan 18, 2023
Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)
Active, not recruiting
- Androgen Receptor Positive
- +5 more
- Enobosarm
- +2 more
-
Corona, California
- +6 more
Jun 8, 2022
Safety Issues, Pain, Pancreas Fibrosis Trial in Washington (Proglumide, Placebo)
Recruiting
- Safety Issues
- +2 more
- Proglumide
- Placebo
-
Washington, District of ColumbiaGeorgetown University
Dec 1, 2022
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer Trial in
Recruiting
- Castration-Resistant Prostatic Cancer
- +4 more
- ARAT
- +2 more
-
Orange City, Florida
- +1 more
Nov 23, 2022
Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)
Not yet recruiting
- Triple-Negative Breast Cancer
- Trastuzumab Deruxtecan
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023
Epidermolysis Bullosa Trial in Redwood City (Serlopitant Tablet, Placebo Oral Tablet)
Completed
- Epidermolysis Bullosa
- Serlopitant Tablet
- Placebo Oral Tablet
-
Redwood City, CaliforniaStanford University
Nov 30, 2022
Monitoring Drug Efficacy in Patients With Alzheimer's Disease
Recruiting
- Alzheimer Disease
- AChE inhibitor monotherapy
- AChE inhibitor and NMDA receptor antagonist combination therapy
-
Manila, Metro Manila, PhilippinesPhilippine General Hospital
Mar 24, 2023
Prostate Cancer, Malignant Tumor of Prostate, Secondary Malignant Tumor of Prostate Trial in Cleveland (drug, other, radiation)
Not yet recruiting
- Prostate Cancer
- +2 more
- Androgen deprivation therapy (ADT)
- +3 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center Seidman Cancer Cen
Nov 21, 2023
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- [177Lu]Lu-PSMA-617
- +3 more
- (no location specified)
Jan 23, 2023
Primary Aldosteronism, Hypertension Trial (Finerenone, Spironolactone)
Not yet recruiting
- Primary Aldosteronism
- Hypertension
- (no location specified)
Apr 3, 2023